alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,051–1,075 of 1,178 studies published 2024 (page 43 of 48) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

High-molecular-weight oligomer tau (HMWoTau) species are dramatically increased in Braak-stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005)

✓ Peer-reviewed alzhub usefulness score 40 out of 100. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2024-11-01

Disease-specific oligomers Tau assay system is anticipated in Alzheimer disease (AD) to elucidate their etiological roles. 4 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

There Is No Direct Causal Relationship Between Coronary Artery Disease and Alzheimer Disease: A Bidirectional Mendelian Randomization Study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of the American Heart Association 2024-07-31

The association between poor cardiovascular health and cognitive decline as well as dementia progression has been inconsistent across studies. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Chemical-Driven Amyloid Clearance for Therapeutics and Diagnostics of Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Accounts of chemical research 2024-11-04

A century ago, German neurologist Alois Alzheimer documented the first case of Alzheimer's disease (AD), illuminating cognitive impairments associated with the presence of abnormal protein clusters, including amyloid plaques and tau tangles, within the brain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The impact of the implementation of a national policy on dementia on healthcare costs in older patients with dementia in Korea: a quasi-experimental difference-in-difference study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet Regional Health - Western Pacific 2024-01-27

Policy implementation was associated with a significant decrease in patient out-of-pocket cost. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Geographic variation in shortfalls of dementia specialists in the United States

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Health Affairs Scholar 2024-06-28

Dementia specialists-neurologists, geriatricians, and geriatric psychiatrists-serve a critical clinical function in diagnosing early-stage Alzheimer's disease and determining eligibility for treatment with disease-modifying therapies. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Geospatial analysis of dementia mortality and its associations with demographic and socioeconomic factors

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Alzheimer s Disease Reports 2024-01-01

This study highlights diverse links between dementia mortality and demographic and socioeconomic factors at the county level in the United States. 5 key findings →

Participants: 2,019 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Intravenous chaperone treatment of late-stage Alzheimer´s disease (AD) mouse model affects amyloid plaque load, reactive gliosis and AD-related genes

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Translational psychiatry 2024-10-24

Treatment strategies that are efficient against established Alzheimer's disease (AD) are needed. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clinical Significance of the Plasma Biomarker Panels in Amyloid-Negative and Tau PET-Positive Amnestic Patients: Comparisons with Alzheimer's Disease and Unimpaired Cognitive Controls

✓ Peer-reviewed alzhub usefulness score 39 out of 100. International journal of molecular sciences 2024-05-21

The purpose of this study was to investigate whether plasma biomarkers can help to diagnose, differentiate from Alzheimer disease (AD), and stage cognitive performance in patients with positron emission tomography (PET)-confirmed primary age-related tauopathy, termed tau-first cognitive proteinopathy (TCP) in this study. 4 key findings →

Participants: 55 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Screening for the Spectrum of Cognitive Impairment in Primary Care: Development of a Machine Learning Informed, Workflow‐Friendly Care Model

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2024-12-01

In the testing cohort, the super learner obtained a concordance statistic (95% confidence interval) of 0.822 (0.810, 0.835), higher than any of the individual ML models (Figure 1), and its predicted risk aligned with observed risk in calibration slope plots (Figure 2). 2 key findings →

Participants: 75 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Characterizing Exposure to Traffic‐Related Air Pollution in a Diverse Alzheimer’s Disease Research Center Cohort

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2024-12-01

Preliminary analysis indicates significant differences in location, ethnoracial background, ADI, and TRAP exposure amongst UCD ADRC participants. 5 key findings →

Participants: 985 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

HOME HEALTH USE BY OLDER ADULTS WITH DEMENTIA: COMPARING MEDICARE ADVANTAGE AND TRADITIONAL MEDICARE

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Innovation in Aging 2024

Skilled home health care (HHC) is a critical service for community-dwelling older adults with dementia, but the majority of evidence about its use and quality is based on Traditional Medicare (TM) beneficiaries. 1 key finding →

Participants: 316,407 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Epileptic seizures induced by pentylenetetrazole kindling accelerate Alzheimer-like neuropathology in 5×FAD mice

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in pharmacology 2024-10-31

Clinical studies have shown that epileptic seizures worsen Alzheimer's disease (AD) pathology and related cognitive deficits; however, the underlying mechanism is unclear. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A combination of long- and short-read genomics reveals frequent p-arm breakpoints within chromosome 21 complex genomic rearrangements

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Genetics in medicine open 2024-06-28

Our results provide further insights into the architecture and underlying mechanisms of complex rearrangements on acrocentric chromosomes. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Breast cancer screening among Medicare Advantage enrollees with dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. BMC Health Services Research 2024-03-05

Mammogram utilization was 16% higher (Prevalence Ratio [PR] 1.16; 95% CI: 1.05, 1.29) among Medicare Advantage enrollees with dementia, compared to their counterparts in fee-for-service Medicare. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed